#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Acute myeloid leukaemia Neoplasm malignant Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Ovarian cancer Colorectal cancer Hepatocellular carcinoma Asthma Dermatitis atopic Dementia Alzheimer's type Type 2 diabetes mellitus Breast cancer metastatic Non-small cell lung cancer metastatic More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Adenovirus infection Anal squamous cell carcinoma Undifferentiated sarcoma MELAS syndrome Infertility female Ewing's sarcoma Nephropathy Osteochondrodysplasia Prader-Willi syndrome Fragile X syndrome Hypoxic-ischaemic encephalopathy Cataract Neuroblastoma Epidermolysis bullosa Non-small cell lung cancer More trials…

    Learn about Rare Diseases

    Hereditary motor and sensory neuropathy – Life with Disease SAPHO syndrome – Treatment Friedreich’s ataxia – Life with Disease Stevens-Johnson syndrome Choroid melanoma – Diagnostics Isodicentric chromosome 15 syndrome – Basic Information Basal cell naevus syndrome – Treatment Kearns-Sayre syndrome Ocular melanoma – Trials in Disease Glomerulonephritis membranous – Diagnostics More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    BLEXIMENIB Iberdomide Prednisone Acetate Cefoxitin GAXILOSE Ltx-315 Imifoplatin Sildenafil Citrate Aticaprant Marstacimab Mk-1942 Mva-209-Fsp-B4 Prednisolone Sodium Succinate Pd01B Vsf1.01 Calcium Pantothenate Bp Bjt-778 Secale Cereale Kpl-404 Tofersen More therapies…

    Learn about Your Condition

    Schizophrenia T-cell lymphoma Cholangiosarcoma Corneal dystrophy Atrial septal defect Laryngeal leukoplakia Rhabdomyosarcoma Bile duct adenocarcinoma Prostate cancer Renal cancer recurrent Factor IX deficiency Lung cancer metastatic Leiomyosarcoma metastatic Peripheral spondyloarthritis Immune-mediated myositis More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden
  1. Clinicaltrials.eu/
  2. EVAGGELISMOS”General Hospital of Athens

EVAGGELISMOS”General Hospital of Athens

Ipsiladou 45-47, Athens, 106 76, Greece

Want to learn more about this study or check if you can participate? Contact us.

  • Study Comparing Subcutaneous and Intravenous Isatuximab with Pomalidomide and Dexamethasone for Adults with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Plasma cell myeloma recurrent
    Investigated Drugs:
    • Isatuximab
    • Montelukast Sodium
    • Dexamethasone
    Czechia France Germany Greece Hungary Italy +4

  • Study Comparing ABBV-383 with Standard Therapies for Adults with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Diphenhydramine
    • Selinexor
    • Bortezomib
    Austria Belgium Czechia Denmark France Germany +7

  • Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Crohn’s Disease

    Not recruiting

    3 1
    Investigated Diseases:
    • Crohn’s disease
    Investigated Drugs:
    • Risankizumab
    Austria Belgium Bulgaria Croatia Czechia Denmark +16

  • Study on the Effectiveness and Safety of Risankizumab for Patients with Moderate to Severe Ulcerative Colitis

    Not recruiting

    3 1
    Investigated Drugs:
    • Risankizumab
    Austria Belgium Bulgaria Croatia Czechia France +13

  • Study on the Long-term Effects of Dupilumab in Preventing Lung Function Decline in Adults with Uncontrolled Moderate to Severe Asthma

    Not recruiting

    3 1
    Investigated Drugs:
    • Dupilumab
    Belgium Bulgaria Greece Hungary Ireland Romania +1

  • Study on Golcadomide and R-CHOP Drug Combination for Patients with Untreated High-risk Large B-cell Lymphoma

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Golcadomide
    • Pegfilgrastim
    • Apixaban
    Austria Bulgaria Czechia Denmark Finland France +11

  • Study Comparing Venetoclax and Dexamethasone with Pomalidomide and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

    Not recruiting

    3 1 1 1
    Investigated Drugs:
    • Betamethasone Sodium Phosphate Ph. Eur
    • Pomalidomide
    • Venetoclax
    Czechia Denmark France Germany Greece Italy +1

  • Study of Venetoclax and Azacitidine for Patients with Acute Myeloid Leukemia After Stem Cell Transplant

    Not recruiting

    3 1 1 1
    Investigated Diseases:
    • Acute myeloid leukaemia
    Investigated Drugs:
    • Azacitidine
    • Venetoclax
    Czechia France Germany Greece Hungary Italy +1

  • Study of ISIS 678354 for Patients with Severe Hypertriglyceridemia

    Not recruiting

    3 1 1
    Investigated Drugs:
    • Isis 678354 Sodium Salt
    Belgium Bulgaria Czechia Denmark Finland France +13

  • Study on Long-Term Safety of Itepekimab for Patients with Chronic Obstructive Pulmonary Disease (COPD)

    Not recruiting

    3 1
    Investigated Drugs:
    • Itepekimab
    Bulgaria Czechia Denmark Estonia France Germany +12
Previous Page
1 … 3 4 5 6
Next Page

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!